colorectal cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Histologically confirmed colorectal adenocarcinoma with progression and/or recurrence in all patients after at least second-line systemic therapy; (2) Patients with definitively inoperable metastatic colorectal adenocarcinoma who have received prior second-line standard chemotherapy (fluorouracil-based, irinotecan, and oxaliplatin must have been used in the standard chemotherapy regimen) and have failed treatment; (3) Sumatriptan may be a third- or fourth-line regimen; (4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2; (5) Normal organ function: a. Haemoglobin =110 g/L b. Absolute neutrophil count = 1.5 × 109 / L c. Platelet count = 100 × 109 / L d. Total serum bilirubin = 6.0mmol/L e. AST and ALT = 3 times the upper limit of normal value, because the abnormal liver function is caused by underlying liver metastases, AST and ALT = 5 times the upper limit of normal value f. Serum creatinine acid = 133 µmol/L (6) Not participating in other clinical studies
Exclusion criteria
Exclusion criteria: (1) Ischaemic heart disease, ischaemic cerebrovascular disease and ischaemic peripheral vascular disease; (2) Severe hepatic impairment; (3) Patients with uncontrolled hypertension; (4) Those with poor compliance or who are participating in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;CA199;Eastern Cooperative Oncology Group Performance Status;LncRNA MALAT1;miR-194-5p;Karnofsky;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| DCR;CEA; | — |
Countries
China
Contacts
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine